Ligand-independent internalization and recycling of the insulin receptor. Effects of chronic treatment of 3T3-C2 fibroblasts with insulin and dexamethasone.
Upon binding insulin at the plasma membrane, the insulin receptor internalizes into the endosomal compartment of the cell with a half-time of approximately 10 min. Our earlier work demonstrated that receptor inactivation (loss of insulin binding capacity) is a regulated process. Long term treatment of cultured cells with insulin or the glucocorticoid dexamethasone increases or decreases, respectively, the rate constant for insulin receptor inactivation (Knutson, V. P., Ronnett, G. V., and Lane, M. D. (1982) Proc. Natl. Acad. Sci. U.S.A. 79, 2822-2826). In these studies, monolayer cultures of 3T3-C2 fibroblasts were chronically treated with insulin or dexamethasone. Subsequently, the surface receptors were labeled with the photoactivatable cross-linking agent 125I-labeled 2-(p-azidosalicylamido)ethyl-1,3'- dithiopropionate -insulin. Following equilibration of the radiolabeled receptor between the plasma membrane and internal pools, the steady-state rate constant for receptor recycling was determined by quantitating the rate at which internal radiolabeled receptor was inserted into the plasma membrane. The steady-state rate constant for this recycling process was the same in control, insulin-treated, or steroid-treated cells (t1/2 = 2h). In contrast, the rate constant for receptor internalization was regulated; the half-times were 10 h for control cells, 5 h for insulin-treated cells, and 19 h for dexamethasone-treated cells. These changes in rate constants for internalization and inactivation lead to changes in the relative numbers of receptor molecules undergoing recycling versus inactivation. Therefore, whereas the recycling of the insulin receptor is not a regulated process, the internalization of surface receptor in the absence of bound ligand is a metabolically controlled step in receptor processing.
Knutson
V P
VP
Department of Pharmacology, University of Texas Health Science Center Medical School, Houston, 77225.
D016475:3T3 Cells; D000818:Animals; D001386:Azides / Q000737:chemistry; D002462:Cell Membrane / Q000378:metabolism; D003432:Cross-Linking Reagents; D003907:Dexamethasone / Q000494:pharmacology*; D006868:Hydrolysis; D007328:Insulin / Q000031:analogs & derivatives / Q000737:chemistry / Q000494:pharmacology*; D008024:Ligands; D051379:Mice; D011869:Radioligand Assay; D011972:Receptor, Insulin / Q000187:drug effects / Q000378:metabolism*
C072184:2-(4-azidosalicylamido)ethyl-1,3-dithiopropionate insulin; D001386:Azides; D003432:Cross-Linking Reagents; D007328:Insulin; D008024:Ligands; D003907:Dexamethasone; D011972:Receptor, Insulin